Well written press release. This is what I was talking about last night. I believe if Herceptin wasn’t added there would have been benefit seen in her2 high expressors. I thought that a peer review on the trial from a few years ago showed dfs not much different between AE37 and Herceptin in that 3+ group. That doesn’t show a statistically significant difference obviously, but Herceptin is basically a cure. But AE37 is safer. You could probably never design a study unless equivalence. Anyway, great press release. I appreciate their expert description in helping to understand that report.